Danaher (NYSE:DHR) agreed to acquire Aldevron, a manufacturer of high-quality plasmid DNA, mRNA and proteins, for approximately $9.6 billion.
Fargo, North Dakota-based Aldevron, which employs approximately 600 people, develops the DNA, mRNA and proteins to serve biotechnology and pharmaceutical customers across research, clinical and commercial applications. It will continue to operate as a standalone company and brand within Danaher’s life sciences business segment.
“We are thrilled to have Aldevron join Danaher’s life sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines,” Danaher President and CEO Rainer Blair said. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster.”
